It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Long noncoding RNAs (lncRNAs) and their crosstalks with other RNAs have been revealed to be closely related to tumorigenesis and development, but their role in invasive pituitary adenoma (IPA) remains largely unclear. In our study, LINC00473 was identified as the most upregulated lncRNA in IPA by whole transcriptome RNA sequencing (RNA-Seq). Further, its related signaling pathway LINC00473/miR-502-3p/KMT5A was obtained by constructing a competing endogenous RNA (ceRNA) regulatory network. Their expression in IPA and non-invasive pituitary adenoma (NIPA) tissues was verified by qRT-PCR. Then the effects and mechanisms of LINC00473 and its ceRNA network on the proliferation of pituitary adenoma (PA) cells were confirmed by gene overexpression or silencing techniques combined with CCK-8 assay, EdU staining, flow cytometry assay, and double luciferase reporter gene assay in PA cell lines AtT-20 and GT1-1 in vitro and in a xenograft model in vivo. LINC00473 is overexpressed in IPA and can promote PA cells proliferation. Mechanistically, overexpression of LINC00473 restricts miR-502-3p through the ceRNA mechanism, upregulates KMT5A expression, and promotes the expression of cyclin D1 and CDK2, which is conducive to the cell cycle process, thereby promoting the proliferation of PA cells, involving IPA progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Kunming Medical University, Institute of Neuroscience, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); 1st Affiliated Hospital of Kunming Medical University, Department of Neurosurgery, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960)
2 1st Affiliated Hospital of Kunming Medical University, Yunnan Key Laboratory of Laboratory Medicine, Yunnan Engineering Technology Center of Digestive disease, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); Genetic Diagnosis Center, Women and Children Hospital, Kunming, China (GRID:grid.285847.4)
3 1st Affiliated Hospital of Kunming Medical University, Department of Neurosurgery, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); Affiliated Hospital of Hubei University of Medicine, Department of Neurosurgery, Xiangyang, China (GRID:grid.285847.4)
4 1st Affiliated Hospital of Kunming Medical University, Department of Neurosurgery, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960); The People’s Hospital of Chuxiong, Department of Neurosurgery, Chuxiong, China (GRID:grid.285847.4)
5 1st Affiliated Hospital of Kunming Medical University, Department of Neurosurgery, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960)
6 Kunming Medical University, Institute of Neuroscience, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960)
7 Kunming Medical University, Biomedical Engineering Research Center, Kunming, China (GRID:grid.285847.4) (ISNI:0000 0000 9588 0960)